CD68 and non-small cell lung carcinoma: The other study preliminarily revealed the predictive value of CD8/PD-L1 or CD68/PD-L1 co-expression for camrelizumab plus chemotherapy as first-line treatment in patients with locally advanced or metastatic NSCLC [8].